Stryker puts about $400M into CMR Surgical and takes an exclusive option to buy the Versius maker outright

Stryker and CMR Surgical said in a joint press release on Oct 12 that Stryker will make a preferred equity investment of about $400 million (£300 million) in the Cambridge, England, surgical robot maker, a stake that also gives Stryker an exclusive option to acquire 100% of CMR's equity later on terms the companies did not disclose.

Stryker becomes the exclusive U.S. sales agent for the Versius soft-tissue robot, while CMR keeps development and commercialisation outside the United States, and Stryker's Group President for Medsurg and Neurotechnology, Andy Pierce, joins CMR's board.

Pierce said Stryker had studied soft-tissue robotics for years and chose Versius for its fit in hospitals and ambulatory surgery centres; the deal still needs regulatory approvals and customary closing conditions.

In MEKAWIRE's funding records, CMR's last disclosed priced amount was a $600 million Series D in June 2021, and its April 2025 equity-and-debt package carries no disclosed figure, so Stryker's cheque is the largest disclosed inflow into the company in five years.